Insilico Applies Deep Learning to Drug Discovery

"The world of artificial intelligence is rapidly evolving and affecting every aspect of our daily life. And soon this progress will be felt in the pharmaceutical industry. We set up the Pharma.AI division to help pharmaceutical companies significantly accelerate their R&D and increase the number of approved drugs, but in the process we came up with over 800 strong hypotheses in oncology, cardiovascular, metabolic and CNS space and started basic validation. We are cautious about making strong statements, but if this approach works, it will uberize the pharmaceutical industry and generate unprecedented number of QALY," said Alex Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

The post Insilico Applies Deep Learning to Drug Discovery appeared first on insideHPC.